Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Deloitte
UBS
Medtronic
Chinese Patent Office
Colorcon
US Army
Healthtrust
McKinsey

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208627

« Back to Dashboard

NDA 208627 describes TPOXX, which is a drug marketed by Siga Technologies and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the TPOXX profile page.

The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
Summary for 208627
Tradename:TPOXX
Applicant:Siga Technologies
Ingredient:tecovirimat
Patents:6
Generic Entry Opportunity Date for 208627
Generic Entry Date for 208627*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 208627
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TPOXX tecovirimat CAPSULE;ORAL 208627 NDA SIGA Technologies, Inc. 50072-200 50072-200-42 42 CAPSULE in 1 BOTTLE (50072-200-42)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Jul 13, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 13, 2025
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
Regulatory Exclusivity Expiration:Jul 13, 2023
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:May 3, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Mallinckrodt
Healthtrust
AstraZeneca
Chinese Patent Office
US Department of Justice
Medtronic
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.